(October 15, 2018) This month in Nature, researchers from Weill Cornell published a study that helps to explain why the body’s natural immune response struggles to fight back against ovarian cancer. Using ovarian tumors from humans and mice, they found that T cells, vital to destroying cancerous cells, are inhibited because of the tumor’s effect … Continued
(October 11, 2018) The BMJ recently published a study from Denmark about the effect that newer birth control pills have on ovarian cancer risk. Researchers focused on two kinds of pills, those which contained both estrogen and progestogen or those which only had progestogen. In this study, rather than having a specific number of people … Continued
(October 9, 2018) A study, published in JAMA Oncology, followed about 200,000 women over the course of 25 years in order to track their use of analgesics. A little over one-thousand of those women developed epithelial ovarian cancer within that time frame. Although researchers didn’t find any significant differences in risk when they evaluated aspirin … Continued
(October 2, 2018) A study by the Mayo Clinic earlier this year aimed to increase the amount of genetic counseling referrals to epithelial ovarian cancer patients by supplying patients with a Genetics Referral Toolkit. The research was funded by OCRA through the SU2C Ovarian Cancer Dream Team. The toolkit included a checklist, a way to … Continued
(October 1) OCRA’s inaugural Super September shopping event took place on September 27-28 at Pier 17 in Manhattan. Guests enjoyed discount designer shopping, a special musical performance from the hit Broadway show Dear Evan Hansen, and so much more.
(October 1, 2018) We’re shortening our name, to make it easier to say and easier to write. OCRFA is now Ovarian Cancer Research Alliance (OCRA). You can find us at ocrahope.org, and on social media at @OCRAHOPE.
(September 21, 2018) In an international collaboration funded in part by OCRFA, published recently in Cell, researchers used proteomics, the large-scale study of proteins, to identify an important indicator for treatment and disease-free survival in patients with high grade serous ovarian cancer. The biomarker, known as CT45, is associated with better response to chemotherapy and … Continued
(September 19, 2018) Researchers at the University of Washington recently made a breakthrough in identifying and confirming variants of the BRCA1 mutation, a gene mutation that increases a woman’s risk of breast and ovarian cancers. Although the most common BRCA1 and BRCA2 mutations are already known to increase risk, there are thousands of variants of … Continued
(September 14, 2018) A study published in Cell Metabolism explores the use of glycogen by ovarian cancer tumor cells, specifically in an area where metastasis happens quickly, the omentum. The omentum, or fatty tissue in the abdomen, is used by the cancer cells for the energy-heavy fat cells to grow. Once that energy source is … Continued
We need your help this September. Ovarian cancer is the fifth leading cause of cancer death among women, and is the deadliest of gynecologic cancers. #ResearchMatters. Research is the key to defeating this devastating disease. That’s why every day, OCRFA-funded scientists are working to find new ways to prevent ovarian cancer, developing better methods to … Continued
(August 30, 2018) Researchers at Brigham and Women’s Hospital in Boston have found new clues to the origin of high-grade serous carcinoma (HGSC). The majority of women who are diagnosed with ovarian cancer have HGSC, and up to 90 percent of those cases go undetected and undiagnosed until the cancer has spread. Previous studies showed the … Continued
Be a voice for the ovarian cancer community. Update: The deadline to apply for our 2019 Advocate Leader program has now passed. (August 28, 2018) Registration is now open for our 2019 Advocate Leader program. Apply today to join our diverse community of survivors, caregivers and activists from across the country using their voices to effect … Continued
Get email updates about research news, action alerts, and ways to join the fight.
